Clinical Study Results
Research Sponsor: AstraZeneca AB
Drug Studied: Anifrolumab
Study Title: A study to find out if anifrolumab reduces lupus symptoms in
participants with lupus
Thank you!
Thank you for taking part in the clinical study for the study drug anifrolumab, also
called MEDI-546. You and all of the participants helped researchers learn more
about anifrolumab to help people with systemic lupus erythematosus, also called
lupus or SLE.
AstraZeneca AB sponsored this study and thinks it is important to share the results
of the study with you and the public. An independent non-profit organization called
CISCRP helped prepare this summary of the study results for you. We hope it
helps you understand and feel proud of your important role in medical research.
If you participated in the study and have questions about the results, please speak
with the doctor or staff at your study site.
What is happening with the study now?
The participants were in the study for up to 15 months, but the entire study took more
than 3 years to finish. The study started in July 2015 and ended in December 2018.
This study included a total of 373 participants from Argentina, Belgium, Brazil,
Bulgaria, Canada, France, Germany, Japan, Lithuania, Mexico, Russia, South
Africa, South Korea, Spain, and the United States.
The sponsor reviewed the data collected when the study ended and created a
report of the results. This is a summary of that report.
1